Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABUS Arbutus Biopharma	$3.58 +2.3%	$3.28	$2.71 ▼ $4.73	$670.34M	1.23	967,220 shs	541,720 shs
GHRS GH Research	$12.83 -7.0%	$10.66	$6.00 ▼ $20.50	$667.52M	0.97	187,402 shs	465,478 shs
RTTR Ritter Pharmaceuticals	$3.80 +0.8%	$2.99	$0.15 ▼ $1.27	$175.29M	-0.43	14.23 million shs	3,849 shs
TRVI Trevi Therapeutics	$6.17 -1.3%	$6.27	$2.36 ▼ $7.48	$616.34M	0.59	1.35 million shs	2.96 million shs

5G Stocks: The Path Forward is Profitable

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABUS Arbutus Biopharma	-1.41%	+2.64%	+4.48%	+5.42%	+10.06%
GHRS GH Research	+7.40%	+10.94%	+35.73%	+26.75%	+14.92%
RTTR Ritter Pharmaceuticals	+3.19%	-3.18%	+4.91%	+25.13%	+1,824.58%
TRVI Trevi Therapeutics	-3.99%	-5.02%	-6.72%	-0.64%	+140.38%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ABUS Arbutus Biopharma	2.2494 of 5 stars	3.5	0.0	0.0	0.0	3.2	2.5	0.6
GHRS GH Research	1.7683 of 5 stars	3.5	0.0	0.0	0.0	2.8	2.5	0.0
RTTR Ritter Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
TRVI Trevi Therapeutics	3.5052 of 5 stars	4.7	2.0	0.0	0.0	2.7	3.3	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABUS Arbutus Biopharma	3.00	Buy	$5.50	53.63% Upside
GHRS GH Research	3.00	Buy	$32.00	149.42% Upside
RTTR Ritter Pharmaceuticals	0.00	N/A	N/A	N/A
TRVI Trevi Therapeutics	3.30	Buy	$18.63	201.86% Upside

Current Analyst Ratings Breakdown

Latest RTTR, ABUS, GHRS, and TRVI Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/4/2025	GHRS GH Research	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$25.00
6/2/2025	TRVI Trevi Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
6/2/2025	TRVI Trevi Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$21.00
5/28/2025	TRVI Trevi Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy ➝ Buy	$21.00
5/20/2025	TRVI Trevi Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$24.00 ➝ $24.00
5/13/2025	GHRS GH Research	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/9/2025	GHRS GH Research	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$32.00 ➝ $29.00
5/9/2025	GHRS GH Research	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$40.00 ➝ $40.00
4/8/2025	TRVI Trevi Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$24.00 ➝ $24.00
3/28/2025	ABUS Arbutus Biopharma	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00 ➝ $5.00
3/19/2025	TRVI Trevi Therapeutics	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$11.00 ➝ $20.00

(Data available from 6/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABUS Arbutus Biopharma	$6.40M	107.09	N/A	N/A	$0.63 per share	5.68
GHRS GH Research	N/A	N/A	N/A	N/A	N/A	N/A
RTTR Ritter Pharmaceuticals	N/A	N/A	N/A	N/A	$0.10 per share	N/A
TRVI Trevi Therapeutics	N/A	N/A	N/A	N/A	$1.29 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABUS Arbutus Biopharma	-$72.85M	-$0.41	N/A	N/A	N/A	-1,137.65%	-68.18%	-51.55%	7/30/2025 (Estimated)
GHRS GH Research	-$35.59M	-$0.79	N/A	N/A	N/A	N/A	-20.29%	-19.49%	N/A
RTTR Ritter Pharmaceuticals	-$10.13M	N/A	N/A	∞	N/A	N/A	N/A	-162.05%	N/A
TRVI Trevi Therapeutics	-$29.07M	-$0.45	N/A	N/A	N/A	N/A	-63.31%	-57.06%	8/14/2025 (Estimated)

Latest RTTR, ABUS, GHRS, and TRVI Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	ABUS Arbutus Biopharma	-$0.09	-$0.13	-$0.04	-$0.13	$2.54 million	$1.76 million
5/8/2025	Q1 2025	GHRS GH Research	-$0.61	-$0.19	+$0.42	-$0.19	N/A	N/A
5/6/2025	Q1 2025	TRVI Trevi Therapeutics	-$0.13	-$0.09	+$0.04	-$0.09	N/A	N/A
3/27/2025	Q4 2024	ABUS Arbutus Biopharma	-$0.08	-$0.07	+$0.01	-$0.07	$2.20 million	$1.57 million
3/18/2025	Q4 2024	TRVI Trevi Therapeutics	-$0.12	-$0.11	+$0.01	-$0.11	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABUS Arbutus Biopharma	N/A	N/A	N/A	N/A	N/A
GHRS GH Research	N/A	N/A	N/A	N/A	N/A
RTTR Ritter Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
TRVI Trevi Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABUS Arbutus Biopharma	N/A	7.02	7.02
GHRS GH Research	N/A	15.83	15.83
RTTR Ritter Pharmaceuticals	N/A	3.67	3.67
TRVI Trevi Therapeutics	N/A	7.38	7.38

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABUS Arbutus Biopharma	43.79%
GHRS GH Research	56.90%
RTTR Ritter Pharmaceuticals	0.84%
TRVI Trevi Therapeutics	95.76%

Insider Ownership

Company	Insider Ownership
ABUS Arbutus Biopharma	20.30%
GHRS GH Research	41.60%
RTTR Ritter Pharmaceuticals	15.40%
TRVI Trevi Therapeutics	18.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABUS Arbutus Biopharma	90	191.53 million	181.91 million	Optionable
GHRS GH Research	10	52.03 million	30.38 million	Optionable
RTTR Ritter Pharmaceuticals	7	46.15 million	N/A	Not Optionable
TRVI Trevi Therapeutics	20	99.89 million	58.13 million	Optionable

RTTR, ABUS, GHRS, and TRVI Headlines

Recent News About These Companies

Trevi Therapeutics (NASDAQ:TRVI) Trading Down 4.8% - Time to Sell?

June 9 at 1:18 PM | marketbeat.com

Two Sigma Investments LP Purchases New Shares in Trevi Therapeutics, Inc. (NASDAQ:TRVI)

June 9 at 3:23 AM | marketbeat.com

Trevi Therapeutics (NASDAQ:TRVI) Downgraded by Wall Street Zen to "Sell"

June 8, 2025 | americanbankingnews.com

Trevi Therapeutics, Inc. (NASDAQ:TRVI) Shares Purchased by Millennium Management LLC

June 7, 2025 | marketbeat.com

Trevi Therapeutics (NASDAQ:TRVI) Stock Rating Lowered by Wall Street Zen

June 7, 2025 | marketbeat.com

Trevi Therapeutics Announces Closing of $115 Million Underwritten Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares

June 5, 2025 | prnewswire.com

Ameriprise Financial Inc. Acquires 63,067 Shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI)

June 5, 2025 | marketbeat.com

Trevi Therapeutics (NASDAQ:TRVI) Shares Gap Up - Time to Buy?

June 4, 2025 | marketbeat.com

D. Boral Capital Reiterates "Buy" Rating for Trevi Therapeutics (NASDAQ:TRVI)

June 4, 2025 | americanbankingnews.com

Brokerages Set Trevi Therapeutics, Inc. (NASDAQ:TRVI) Target Price at $18.63

June 4, 2025 | americanbankingnews.com

Trevi Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock

June 3, 2025 | prnewswire.com

Trevi Therapeutics (NASDAQ:TRVI) Stock Price Down 7.1% - Here's Why

June 3, 2025 | marketbeat.com

Trevi Therapeutics Announces Proposed Public Offering of Common Stock

June 2, 2025 | prnewswire.com

Trevi Therapeutics Showcases Drug That Cuts Cough Frequency In Lung Disease Patients

June 2, 2025 | benzinga.com

Trevi Therapeutics (NASDAQ:TRVI) Reaches New 12-Month High - What's Next?

June 2, 2025 | marketbeat.com

Trevi Therapeutics' (TRVI) "Buy" Rating Reiterated at D. Boral Capital

June 2, 2025 | marketbeat.com

Trevi Therapeutics Announces Positive Topline Results from the Phase 2b CORAL Trial of Haduvio in Patients with Idiopathic Pulmonary Fibrosis Chronic Cough

June 2, 2025 | prnewswire.com

Trevi Therapeutics to Host Conference Call and Webcast on June 2nd to Share Topline Results from the Phase 2b CORAL Trial of Haduvio in Patients with Idiopathic Pulmonary Fibrosis Chronic Cough

June 1, 2025 | prnewswire.com

Trevi Therapeutics, Inc. (NASDAQ:TRVI) Given Average Rating of "Buy" by Analysts

June 1, 2025 | marketbeat.com

Research Analysts Issue Forecasts for TRVI Q2 Earnings

May 31, 2025 | marketbeat.com

H.C. Wainwright Initiates Coverage of Trevi Therapeutics (TRVI) With Buy Rating

May 29, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

RTTR, ABUS, GHRS, and TRVI Company Descriptions

Arbutus Biopharma NASDAQ:ABUS

$3.58 +0.08 (+2.29%)

As of 04:00 PM Eastern

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.

GH Research NASDAQ:GHRS

$12.83 -0.96 (-6.96%)

As of 04:00 PM Eastern

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). The company's lead program is GH001, an inhalable mebufotenin product candidate, currently under Phase 2b clinical trial for the treatment of patients with TRD, as well as Phase 2a clinical trials for the treatment of Bipolar II disorder and postpartum depression. It is also involved in the development of GH002, an intravenous mebufotenin product candidate for IV administration, currently under Phase 1 clinical trials for the treatment of psychiatric or neurological disorder; and GH003, an intranasal mebufotenin product candidate for nasal administration, which is currently in preclinical development with a focus on psychiatric and neurological disorders. The company was founded in 2018 and is based in Dublin, Ireland.

Ritter Pharmaceuticals NASDAQ:RTTR

Ritter Pharmaceuticals, Inc. develops and sells novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. Its lead product candidate is RP-G28, a novel microbiome modulator, which has completed Phase 2b clinical trial for the reduction of symptoms associated with lactose intolerance. The company's product, RP-G28 is designed to stimulate the growth of lactose-metabolizing bacteria in the colon, thereby adapting the gut microbiome to assist in digesting the lactose that reaches the large intestine. The company was formerly known as Ritter Natural Sciences, LLC and changed its name to Ritter Pharmaceuticals, Inc. in September 2008. Ritter Pharmaceuticals, Inc. was founded in 2004 and is headquartered in Los Angeles, California.

Trevi Therapeutics NASDAQ:TRVI

$6.17 -0.08 (-1.28%)

As of 04:00 PM Eastern

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER (CORAL) clinical trial for treatment of chronic cough in patients with IPF; phase 2a Refractory Chronic Cough Improvement Via NAL ER (RIVER) clinical trial for reducing chronic cough in RCC patients; phase 2 clinical trial in patients with pruritus; phase 2b/3 clinical trial in patients with prurigo nodularis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time